6-Fluoro-N,N-dimethyltryptamine (6-Fluoro-DMT) is a synthetic drug of the tryptamine chemical class.
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
ChemSpider | |
Chemical and physical data | |
Formula | C12H15FN2 |
Molar mass | 206.264 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Effects
edit6-Fluoro-DMT is said to not be active as a hallucinogen in humans due to being "metabolically blocked".[1]
Pharmacology
edit6-Fluoro-DMT possess affinity for the 5-HT1A (392.6 nM), 5-HT1B (217.7 nM), 5-HT1D (55.4 nM), 5-HT1E (460.8 nM), 5-HT2A (866 nM), 5-HT2B (29.8 nM), 5-HT2C (674.2 nM), 5-HT5A (960.5 nM), 5-HT6 (25.6 nM), 5-HT7 (40.8 nM), D1 (547.3 nM), D2 (610.4 nM), D3 (866.8 nM), D4 (1,454 nM), D5 (6,291 nM), α1A-adrenergic (173.3 nM), α2B-adrenergic (295.5 nM), α2C-adrenergic (148.8 nM), H1 (46.6 nM), H2 (925.4 nM), I1 (898.4 nM), 1 (6,892 nM), and 2 (7,128 nM) receptors, as well as the SERT (144.6 nM).[2] It has low/negligible (> 10,000 nM) affinity for the 5-HT3, α1B-adrenergic, α2A-adrenergic, β1-adrenergic, β2-adrenergic, H3, H4, and M1-M5 receptors, as well as the DAT and NET.[2] It has not been screened at 5-HT1F, 5-HT4, α1D-adrenergic, β3-adrenergic, or VMAT1/VMAT2.
History
edit6-Fluoro was first described in the scientific literature by 1980.[1]
See also
editReferences
edit- ^ a b Kline, Toni Beth (1980). "Structure-Activity Relationships Of N,N-Dialkyltryptamines Substituted In The Benzene Moiety". UAB Digital Commons. Retrieved 15 November 2024.
Neither 6-hydroxy DMT, 5-methoxy-6-hydroxy DMT, nor the metabolically blocked 6-fluoro DMT are active hallucinogens in man.
- ^ a b Ray TS (February 2010). "Psychedelics and the human receptorome". PLOS ONE. 5 (2): e9019. Bibcode:2010PLoSO...5.9019R. doi:10.1371/journal.pone.0009019. PMC 2814854. PMID 20126400.